



Kala Pharmaceuticals to Present Data at the Controlled Release Society 2013 Annual Meeting

Preclinical Data Highlight Kala's Proprietary Mucosal-Penetrating Particle Technology for Ocular Delivery

Waltham, Mass., July 19, 2013 – Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI. The poster presentation will highlight the capability of Kala's proprietary Mucosal-Penetrating Particle (MPP) technology to enhance topical drug delivery to the front and back of the eye.

Poster Presentation:

(Abstract #100749, Poster #696): Monday, July 22, 2013, 9:30-10:30am HST, "**Mucosal-Penetrating Particles Enable Topical Delivery to Posterior Segment of the Eye**" Elizabeth Enlow, Kala Pharmaceuticals, Poster Session #1, Hawaii Convention Center.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is developing innovative products which are capable of penetrating mucosal barriers for the treatment of major diseases that affect the eyes, lungs, gastrointestinal tract, and female reproductive system. Mucosal barriers have been largely overlooked as a limitation for drug efficacy. Using the company's proprietary technology platform, Kala's Mucosal-Penetrating Products (MPPs) have the unique ability to rapidly and uniformly coat and permeate mucosal tissues leading to highly effective treatments with improved side effect profiles. The company is leveraging its platform as an internal product engine for a wide spectrum of potential applications, including treatments for respiratory, ophthalmic, female reproductive tract and gastrointestinal diseases. Kala is also pursuing collaborations with partners to transform the therapeutic properties of marketed drugs and compounds in development. Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, Dr. Justin Hanes of The Johns Hopkins University School of Medicine, Dr. Robert Langer of the Massachusetts Institute of Technology, and Dr. Colin Gardner formerly of TransForm Pharmaceuticals/Johnson & Johnson and Merck. The company is now backed by leading investors including Lux Capital, Polaris Venture Partners, Third Rock Ventures and, Crown Venture Fund, LLC. For more information, please visit www.kalarx.com.

Contact:

Kala Pharmaceuticals, Inc.

Tel: 781 810 4748

info@kalarx.com

Media:

Gina Nugent

The Yates Network

gina@theyatesnetwork.com

